Linagliptin

Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes

Retrieved on: 
Wednesday, December 7, 2022
Health, Diabetes, Clinical Trials, Research, Pharmaceutical, Science, Lykke, Eli Lilly and Company, Insulin, LLY, Ageing, Exercise, Linagliptin, Pediatrics, International Diabetes Federation, Risk, Adolescence, Empagliflozin, Prevalence, Fasting, Joslin Diabetes Center, NYSE, World Diabetes Day, Diabetes, International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Type 2 diabetes, Obesity, Face, Multimedia, Diet, Metformin, Safety, SGLT2, Harvard Medical School, Boehringer Ingelheim, IDF, New product development, Pharmaceutical industry, Glycated hemoglobin

View the full release here: https://www.businesswire.com/news/home/20221207005405/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221207005405/en/
    The DINAMO (DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents) trial included youth aged 10-17 years with type 2 diabetes and HbA1c 6.5% and 10.5%.
  • Participants were randomly assigned treatment with empagliflozin (10 or 25 mg) (n=52), linagliptin (5 mg) (n=53) or placebo (n=53) once daily.
  • Todays results from the DINAMO global clinical trial demonstrated that the SGLT2 inhibitor empagliflozin compared with placebo significantly improved overall blood sugar control in children and adolescents with type 2 diabetes.
  • A numerical reduction of 0.34% (P=0.2935) was observed.1
    The findings have been submitted for publication in a peer-reviewed journal.

Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Markets 2020-2021 & 2026: Focus on Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others - ResearchAndMarkets.com

Retrieved on: 
Monday, September 20, 2021
Health, Pharmaceutical, DPP-4, Linagliptin, Vildagliptin, Bristol-Myers Squibb Co. v. Superior Court, IDF, Merck & Co., GlaxoSmithKline, Diabetes, Novartis, Growth, Prevalence, E-64, International Diabetes Federation, Anagliptin, Pharmaceutical industry, Fine chemical

The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.

Key Points: 
  • The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.
  • However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors in form of drugs challenge the growth of the market.
  • The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type.
  • Geographically, the global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

CARMELINA® subgroup analysis supports long-term cardiovascular and renal safety of linagliptin in older people with type 2 diabetes

Retrieved on: 
Wednesday, February 12, 2020
Cardiology, Seniors, Pharmaceutical, Health, Hospitals, Consumer, Clinical trials, Other Health, RTT, Organ systems, Organic compounds, Health, Boehringer Ingelheim, Diabetes management, Dipeptidyl peptidase-4 inhibitor, Eli Lilly and Company, Linagliptin, Diabetes, Empagliflozin/linagliptin, Empagliflozin, CARMELINA®, Trajenta® (linagliptin), our cardiovascular outcome trials

As the older population also has the highest incidence of type 2 diabetes of any age group, this analysis will be invaluable in helping clinicians manage the treatment of this patient group, previously underrepresented in clinical studies.

Key Points: 
  • As the older population also has the highest incidence of type 2 diabetes of any age group, this analysis will be invaluable in helping clinicians manage the treatment of this patient group, previously underrepresented in clinical studies.
  • The results should reassure healthcare professionals that linagliptin is suitable for a wide patient population to improve glycemic control whilst ensuring cardiovascular and renal safety.
  • CARMELINA was led by an academic trial steering committee and the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance.
  • Cardiovascular outcome trials are highly clinically relevant, as cardiovascular disease is a major complication and the leading cause of death in type 2 diabetes.

Linagliptin (CAS 668270-12-0) Market Research Report 2019

Retrieved on: 
Tuesday, August 20, 2019
Organic compounds, Dipeptidyl peptidase-4 inhibitors, Eli Lilly and Company, Chemical compounds, RTT, Linagliptin, Quinazolines, Market research

Dublin, Aug. 20, 2019 (GLOBE NEWSWIRE) -- The "Linagliptin (CAS 668270-12-0) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Dublin, Aug. 20, 2019 (GLOBE NEWSWIRE) -- The "Linagliptin (CAS 668270-12-0) Market Research Report 2019" report has been added to ResearchAndMarkets.com's offering.
  • This Global Report 2019 is a result of industry experts' diligent work on Researching the world market of Linagliptin.
  • The forth chapter deals with Linagliptin market trends review, distinguish Linagliptin manufacturers and suppliers.
  • The Linagliptin global market Report 2019 key points:

Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®

Retrieved on: 
Tuesday, June 11, 2019
Health, Biotechnology, Cardiology, Clinical trials, Pharmaceutical, Research, Science, Dipeptidyl peptidase-4 inhibitors, RTT, Chemical compounds, Organic compounds, Piperidines, Organ systems, Linagliptin, Diabetes, Gemigliptin, Metformin

These data can further support physicians in choosing the most appropriate glucose-lowering treatment for each individual patient.

Key Points: 
  • These data can further support physicians in choosing the most appropriate glucose-lowering treatment for each individual patient.
  • But, physicians considering additional therapies to lower blood glucose for their patients need a DPP-4 inhibitor with an established long-term safety profile.
  • These new data from CAROLINA, along with data from the placebo-controlled cardiovascular outcome trial CARMELINA, expand the evidence and experience with linagliptin, to provide healthcare professionals with confidence in the long-term safety profile across a broad range of patients with type 2 diabetes.
  • CAROLINA is the only DPP-4 inhibitor, active-comparator cardiovascular outcome trial.

Linagliptin and Glimepiride Have Comparable Cardiovascular Safety Effects in Type 2 Diabetes at High Cardiovascular Risk

Retrieved on: 
Tuesday, June 11, 2019
RTT, Organic compounds, Organ systems, Medical specialties, Glimepiride, Sulfonylurea, Anti-diabetic medication, Dipeptidyl peptidase-4 inhibitor, Linagliptin, Cardiovascular disease, Insulin, Diabetes

The study was featured today at "The CAROLINA TrialFirst Results of the Cardiovascular Outcomes Trial Comparing Linagliptin vs. Glimepiride" symposium.

Key Points: 
  • The study was featured today at "The CAROLINA TrialFirst Results of the Cardiovascular Outcomes Trial Comparing Linagliptin vs. Glimepiride" symposium.
  • CVD is a major risk for and the leading cause of death for people living with T2D, and since 2008, the FDA requires diabetes medications to demonstrate cardiovascular (CV) safety.
  • Although linagliptin and glimepiride work differently, they both lower glucose levels by stimulating the body's insulin production.
  • "In CAROLINA, we wanted to test this question using a current-generation sulfonylurea, and we found that glimepiride does not increase cardiovascular risk relative to linagliptin.

Dipeptide Peptidase 4 (DPP-4) Inhibitors: Global Market 2019-2024 - The Tradjenta Market will Surpass Merck's Januvia During the Forecast Period - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2019
Health, Pharmaceutical, Chemical compounds, Dipeptidyl peptidase-4 inhibitors, Organic compounds, Chemistry, Dipeptidyl peptidase-4, Sitagliptin, Linagliptin, Forecast period, Compound annual growth rate, Vildagliptin

The "Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • Increase in clinical trials on the DPP-4 drugs will also boost the market growth in the forecast period.
  • The global Tradjenta market is expected to register a CAGR of 5.7 %, during the forecast period, 2019-2024, and is expected to surpass the Januvia market, which held the maximum market share in 2018.
  • The Asia-Pacific holds 32% of the market share in the global DPP-4 market, followed by North America, which holds the highest market share.

Boehringer Ingelheim and Lilly’s CAROLINA® cardiovascular outcome trial for Trajenta® meets primary endpoint of non-inferiority compared to glimepiride

Retrieved on: 
Thursday, February 14, 2019
Health, Biotechnology, Cardiology, Clinical trials, Pharmaceutical, Diabetes, Dipeptidyl peptidase-4 inhibitors, Diabetes, Organic compounds, Chemical compounds, Piperidines, Linagliptin, Organ systems, Boehringer Ingelheim, Diabetes mellitus type 2, Diabetes management, Omarigliptin, Discovery and development of dipeptidyl peptidase-4 inhibitors

Many guidelines recommend early use of a diabetes treatment with cardiovascular benefit, said Waheed Jamal, MD, Corporate Vice President and Head of Cardiovascular & Metabolic Medicine, Boehringer Ingelheim.

Key Points: 
  • Many guidelines recommend early use of a diabetes treatment with cardiovascular benefit, said Waheed Jamal, MD, Corporate Vice President and Head of Cardiovascular & Metabolic Medicine, Boehringer Ingelheim.
  • When other therapies such as DPP-4 inhibitors are considered for people with type 2 diabetes, physicians need a treatment with an established long-term safety profile.
  • With these results, CAROLINA expands our understanding of the long-term cardiovascular safety of linagliptin, which now has one of the most comprehensive datasets on the cardiovascular safety of a DPP-4 inhibitor.
  • CAROLINA is the first DPP-4 inhibitor, active-comparator cardiovascular outcome trial.

Global DPP-IV Inhibitors Industry

Retrieved on: 
Wednesday, October 17, 2018
Chemistry, Dipeptidyl peptidase-4 inhibitors, Organic chemistry, Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin, Alogliptin, Daiichi Sankyo, Discovery and development of dipeptidyl peptidase-4 inhibitors, Omarigliptin

Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date

Key Points: 
  • Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date
    Table 1: Global DPP-4 Inhibitor Market by Top Five Drug Class (2018): Market Share Breakdown of Revenues (In %) for Januvia/Janumet, Galvus, Onglyza, Tradjenta, and Nesina (includes corresponding Graph/Chart)
    TECOS Results Prove No Link of Januvia with CVD Events; However, FDA Adds Heart Failure Warning to Label
    Table 2: Prices of Select Dpp4 and Sglt-2 Inhibitors: Single and Combination Drugs
    Table 10: Healthcare Spending (in US$ Billion) by People with Diabetes (20-79 Years) for the Years 2011, 2013, 2015 and 2017 (includes corresponding Graph/Chart)
    Table 14: World 10-Year Perspective for Januvia (Sitagliptin) Franchise Sales Breakdown for Years 2015, 2018 and 2024 for the US and RoW (includes corresponding Graph/Chart)
    Table 17: Global 10-Year Perspective for Onglyza (Saxagliptin) Sales Breakdown for Years 2015, 2018 and 2
    Table 19: Global 10-Year Perspective for Tradjenta (Linagliptin) Sales Breakdown for Years 2015, 2018 and 2
    Table 21: Global 10-Year Perspective for Nesina (Alogliptin): Annual Sales Breakdown for Years 2015, 2018 and 2024 for the US and RoW (includes corresponding Graph/Chart)
    TENELIA (Mitsubishi Tanabe & Daiichi Sankyo Co., Ltd.)
    Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd.
  • Announces the Launch of CANALIA Combination Tablets
    Table 22: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)
    Table 23: World 10-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart)
    Table 24: World Recent Past, Current and Future Analysis for DPP-IV Inhibitors by Drug Compound - Sitagliptin, Saxagliptin, Vildagliptin, and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)
    Table 25: World 10-Year Perspective for DPP-IV Inhibitors by Drug Compound - Percentage Breakdown of Dollar Sales for Sitagliptin, Saxagliptin, Vildagliptin, and Others Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart)
    Table 27: World 10-Year Perspective for Sitagliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2
    Table 29: World 10-Year Perspective for Saxagliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2
    Table 31: World 10-Year Perspective for Linagliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2
    Table 33: World 10-Year Perspective for Alogliptin by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2015, 2018 and 2

Boehringer Ingelheim and Lilly present full results of Tradjenta®'s CARMELINA® cardiovascular outcome trial

Retrieved on: 
Thursday, October 4, 2018
Health, States of Germany, Anti-diabetic drugs, Chemistry, Glucosides, SGLT2 inhibitors, Boehringer Ingelheim, Empagliflozin, Linagliptin, Gliflozin, Eli Lilly and Company, Boehringer

CARMELINA was led by an academic trial steering committee and the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance.

Key Points: 
  • CARMELINA was led by an academic trial steering committee and the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance.
  • In 2015, Boehringer Ingelheim and Eli Lilly and Company announced results from the landmark cardiovascular outcome trial EMPA-REG OUTCOME with the SGLT2 inhibitor empagliflozin.
  • CAROLINA, will be the first DPP-4 inhibitor cardiovascular outcome trial to compare commonly used second line treatments Tradjenta and the sulfonylurea glimepiride.
  • Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, Conn., is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.